Russell Dahl

List of Publications by Year
in descending order

64 papers	2,950 citations	117625 34 h-index	168389 53 g-index
67 all docs	67 docs citations	67 times ranked	4627 citing authors

#	Article	IF	Citations
1	Small Molecular Allosteric Activator of the Sarco/Endoplasmic Reticulum Ca2+-ATPase (SERCA) Attenuates Diabetes and Metabolic Disorders. Journal of Biological Chemistry, 2016, 291, 5185-5198.	3.4	137
2	Small Molecules Can Selectively Inhibit Ephrin Binding to the EphA4 and EphA2 Receptors. Journal of Biological Chemistry, 2008, 283, 29461-29472.	3.4	123
3	Novel MT1-MMP Small-Molecule Inhibitors Based on Insights into Hemopexin Domain Function in Tumor Growth. Cancer Research, 2012, 72, 2339-2349.	0.9	122
4	LYP inhibits T-cell activation when dissociated from CSK. Nature Chemical Biology, 2012, 8, 437-446.	8.0	118
5	BI-97C1, an Optically Pure Apogossypol Derivative as Pan-Active Inhibitor of Antiapoptotic B-Cell Lymphoma/Leukemia-2 (Bcl-2) Family Proteins. Journal of Medicinal Chemistry, 2010, 53, 4166-4176.	6.4	102
6	Small-molecule activation of SERCA2a SUMOylation for the treatment of heart failure. Nature Communications, 2015, 6, 7229.	12.8	102
7	HTS Identifies Novel and Specific Uncompetitive Inhibitors of the Two-Component NS2B-NS3 Proteinase of West Nile Virus. Assay and Drug Development Technologies, 2007, 5, 737-750.	1.2	95
8	Discovery and Validation of a Series of Aryl Sulfonamides as Selective Inhibitors of Tissue-Nonspecific Alkaline Phosphatase (TNAP). Journal of Medicinal Chemistry, 2009, 52, 6919-6925.	6.4	95
9	Preclinical Studies of Celastrol and Acetyl Isogambogic Acid in Melanoma. Clinical Cancer Research, 2007, 13, 6769-6778.	7.0	89
10	Discovery of Enzyme Modulators via High-Throughput Time-Resolved FRET in Living Cells. Journal of Biomolecular Screening, 2014, 19, 215-222.	2.6	88
11	Fully Automated Continuous Flow Synthesis of Highly Functionalized Imidazo[1,2-a] Heterocycles. Organic Letters, 2010, 12, 412-415.	4.6	87
12	Endoplasmic reticulum protein BI-1 regulates Ca²⁺-mediated bioenergetics to promote autophagy. Genes and Development, 2012, 26, 1041-1054.	5.9	83
13	Novel Targeted System To Deliver Chemotherapeutic Drugs to EphA2-Expressing Cancer Cells. Journal of Medicinal Chemistry, 2012, 55, 2427-2436.	6.4	79
14	A Gatekeeper Residue for NEDD8-Activating Enzyme Inhibition by MLN4924. Cell Reports, 2012, 1, 309-316.	6.4	75
15	High-Throughput FRET Assay Yields Allosteric SERCA Activators. Journal of Biomolecular Screening, 2013, 18, 97-107.	2.6	74
16	Rapid Multistep Synthesis of 1,2,4-Oxadiazoles in a Single Continuous Microreactor Sequence. Journal of Organic Chemistry, 2008, 73, 7219-7223.	3.2	73
17	In vivo antitumor effect of a novel inhibitor of protein geranylgeranyltransferase-I. Molecular Cancer Therapeutics, 2009, 8, 1218-1226.	4.1	72
18	The mGluR2 Positive Allosteric Modulator BINA Decreases Cocaine Self-Administration and Cue-Induced Cocaine-Seeking and Counteracts Cocaine-Induced Enhancement of Brain Reward Function in Rats. Neuropsychopharmacology, 2010, 35, 2021-2036.	5.4	72

#	Article	IF	Citations
19	Design, Synthesis, and Structureâ^'Activity Relationship of Substrate Competitive, Selective, and in Vivo Active Triazole and Thiadiazole Inhibitors of the c-Jun N-Terminal Kinase. Journal of Medicinal Chemistry, 2009, 52, 1943-1952.	6.4	71
20	A Surprising Dipolar Cycloaddition Provides Ready Access to Aminoglycosides. Journal of the American Chemical Society, 2004, 126, 8356-8357.	13.7	63
21	Apogossypol derivatives as antagonists of antiapoptotic Bcl-2 family proteins. Molecular Cancer Therapeutics, 2009, 8, 904-913.	4.1	58
22	Apogossypol Derivatives as Pan-Active Inhibitors of Antiapoptotic B-Cell Lymphoma/Leukemia-2 (Bcl-2) Family Proteins. Journal of Medicinal Chemistry, 2009, 52, 4511-4523.	6.4	55
23	Fragment-Based Design of Small Molecule X-Linked Inhibitor of Apoptosis Protein Inhibitors. Journal of Medicinal Chemistry, 2008, 51, 7111-7118.	6.4	53
24	Pharmacological inhibition of PHOSPHO1 suppresses vascular smooth muscle cell calcification. Journal of Bone and Mineral Research, 2013, 28, 81-91.	2.8	52
25	Discovery of a Novel Series of Inhibitors of Lymphoid Tyrosine Phosphatase with Activity in Human T Cells. Journal of Medicinal Chemistry, 2011, 54, 1640-1654.	6.4	46
26	Recent Progress in the Synthesis and Characterization of Group II Metabotropic Glutamate Receptor Allosteric Modulators. ACS Chemical Neuroscience, 2011, 2, 382-393.	3.5	46
27	Design and Synthesis of an Orally Active Metabotropic Glutamate Receptor Subtype-2 (mGluR2) Positive Allosteric Modulator (PAM) That Decreases Cocaine Self-Administration in Rats. Journal of Medicinal Chemistry, 2011, 54, 342-353.	6.4	44
28	An Optically Pure Apogossypolone Derivative as Potent Pan-Active Inhibitor of Anti-Apoptotic Bcl-2 Family Proteins. Frontiers in Oncology, 2011, 1, 28.	2.8	43
29	Dual-Specificity Phosphatase 3 Deficiency or Inhibition Limits Platelet Activation and Arterial Thrombosis. Circulation, 2015, 131, 656-668.	1.6	42
30	Potent, Selective, and Orally Available Benzoisothiazolone Phosphomannose Isomerase Inhibitors as Probes for Congenital Disorder of Glycosylation Ia. Journal of Medicinal Chemistry, 2011, 54, 3661-3668.	6.4	39
31	Phosphomannose Isomerase Inhibitors Improve N-Glycosylation in Selected Phosphomannomutase-deficient Fibroblasts. Journal of Biological Chemistry, 2011, 286, 39431-39438.	3.4	39
32	A new target for Parkinsonâ€™s disease: Small molecule SERCA activator CDN1163 ameliorates dyskinesia in 6-OHDA-lesioned rats. Bioorganic and Medicinal Chemistry, 2017, 25, 53-57.	3.0	39
33	A new target for Alzheimerâ€™s disease: A small molecule SERCA activator is neuroprotective in vitro and improves memory and cognition in APP/PS1 mice. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 1591-1594.	2.2	39
34	Design and Synthesis of Systemically Active Metabotropic Glutamate Subtype-2 and -3 (mGlu_{2/3}) Receptor Positive Allosteric Modulators (PAMs): Pharmacological Characterization and Assessment in a Rat Model of Cocaine Dependence. Journal of Medicinal Chemistry, 2014, 57, 4154-4172.	6.4	36
35	Determination of logâ€‰D via Automated Microfluidic Liquidâ^'Liquid Extraction. Journal of Medicinal Chemistry, 2008, 51, 5140-5142.	6.4	35
36	Synthesis and Biological Evaluation of Apogossypolone Derivatives as Pan-active Inhibitors of Antiapoptotic B-Cell Lymphoma/Leukemia-2 (Bcl-2) Family Proteins. Journal of Medicinal Chemistry, 2010, 53, 8000-8011.	6.4	34

#	Article	IF	Citations
37	Discovery of 5-((5-chloro-2-methoxyphenyl)sulfonamido)nicotinamide (SBI-425), a potent and orally bioavailable tissue-nonspecific alkaline phosphatase (TNAP) inhibitor. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 31-34.	2.2	32
38	Inhibition of Hematopoietic Protein Tyrosine Phosphatase Augments and Prolongs ERK1/2 and p38 Activation. ACS Chemical Biology, 2012, 7, 367-377.	3.4	31
39	Design, Synthesis and Bioevaluation of an EphA2 Receptorâ€Based Targeted Delivery System. ChemMedChem, 2014, 9, 1403-1412.	3.2	31
40	Design, Synthesis, and Structureâ^'Activity Relationships of 3-Ethynyl-1H-indazoles as Inhibitors of the Phosphatidylinositol 3-Kinase Signaling Pathway. Journal of Medicinal Chemistry, 2010, 53, 8368-8375.	6.4	27
41	Inhibition of Bfl-1 with N-aryl maleimides. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 6560-6564.	2.2	24
42	Discovery of 2-(5-nitrothiazol-2-ylthio)benzo[d]thiazoles as novel c-Jun N-terminal kinase inhibitors. Bioorganic and Medicinal Chemistry, 2009, 17, 2712-2717.	3.0	23
43	Orally Active Metabotropic Glutamate Subtype 2 Receptor Positive Allosteric Modulators: Structureâ€"Activity Relationships and Assessment in a Rat Model of Nicotine Dependence. Journal of Medicinal Chemistry, 2012, 55, 9434-9445.	6.4	23
44	Anti-HIV-1 entry optimization of novel imidazopiperidine-tropane CCR5 antagonists. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 1498-1501.	2.2	22
45	High-Throughput Fluorescence Polarization Assay for Chemical Library Screening against Anti-Apoptotic Bcl-2 Family Member Bfl-1. Journal of Biomolecular Screening, 2012, 17, 350-360.	2.6	22
46	Design, synthesis and evaluation of benzoisothiazolones as selective inhibitors of PHOSPHO1. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 4308-4311.	2.2	22
47	Synthesis and optimization of thiadiazole derivatives as a novel class of substrate competitive c-Jun N-terminal kinase inhibitors. Bioorganic and Medicinal Chemistry, 2010, 18, 590-596.	3.0	21
48	The design and synthesis of novel Î±-ketoamide-based p38 MAP kinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 1772-1777.	2.2	20
49	Optimization of Î±-ketoamide based p38 inhibitors through modifications to the region that binds to the allosteric site. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 4819-4824.	2.2	20
50	Alamar blue reagent interacts with cell-culture media giving different fluorescence over time: Potential for false positives. Journal of Pharmacological and Toxicological Methods, 2014, 70, 195-198.	0.7	19
51	Design, synthesis, and structureâ€"activity relationship studies of thiophene-3-carboxamide derivatives as dual inhibitors of the c-Jun N-terminal kinase. Bioorganic and Medicinal Chemistry, 2011, 19, 2582-2588.	3.0	14
52	â€˜Reverseâ€™ Î±-ketoamide-based p38 MAP kinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 5456-5459.	2.2	11
53	Chemical Biology Strategy Reveals Pathway-Selective Inhibitor of NF-ÎºB Activation Induced by Protein Kinase C. ACS Chemical Biology, 2010, 5, 287-299.	3.4	11
54	KR-003048, a potent, orally active inhibitor of p38 mitogen-activated protein kinase. European Journal of Pharmacology, 2010, 632, 93-102.	3.5	10

#	Article	IF	Citations
55	Small molecule SUMOylation activators are novel neuroprotective agents. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 405-409.	2.2	10
56	Discovery and Binding Studies on a Series of Novel Pin1 Ligands. Chemical Biology and Drug Design, 2009, 73, 369-379.	3.2	9
57	Inhibition of the Hematopoietic Protein Tyrosine Phosphatase by Phenoxyacetic Acids. ACS Medicinal Chemistry Letters, 2011, 2, 113-118.	2.8	7
58	Identification of a selective inhibitor of murine intestinal alkaline phosphatase (ML260) by concurrent ultra-high throughput screening against human and mouse isozymes. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 1000-1004.	2.2	6
59	Design and NMR Studies of Cyclic Peptides Targeting the Nâ€Terminal Domain of the Protein Tyrosine Phosphatase YopH. Chemical Biology and Drug Design, 2011, 77, 12-19.	3.2	5
60	Stereo- and regiospecific formation of a highly functionalized bridgehead tricyclic sultam. Tetrahedron Letters, 2002, 43, 4407-4409.	1.4	4
61	Cytoprotective small molecule modulators of endoplasmic reticulum stress. Bioorganic and Medicinal Chemistry, 2016, 24, 2382-2388.	3.0	4
62	Efficient Access to Aminomannoside Derivatives via Formal [2+2] Cycloaddition of Triazolinediones and Tri-O-acetyl-d-glucal. Synthesis, 2010, 2010, 2292-2296.	2.3	1
63	Phosphomannose isomerase inhibitors improve N-glycosylation in selected phosphomannomutase-deficient fibroblasts.. Journal of Biological Chemistry, 2011, 286, 43588.	3.4	0
64	Inhibition of Hematopoietic Protein Tyrosine Phosphatase Augments and Prolongs ERK1/2 and p38 Activation. FASEB Journal, 2012, 26, 766.12.	0.5	0